1. Introduction {#sec1}
===============

Parkinson\'s disease (PD), the second most common neurodegenerative disease after Alzheimer\'s disease, consists of two major pathological hallmarks: loss of dopaminergic neurons and the presence of Lewy bodies (LB). The classic manifestations of PD are characterized by resting tremor, rigidity, bradykinesia, and impairment of postural reflexes. In addition, some untypical nonmotor features, such as sleep disturbances, mood disorders, autonomic dysfunction, sensory problems, and cognitive impairment, are highly concerned recently. Even when treated with effective therapies, PD is progressive and somehow leads to disability or even mortality.

Increasing evidence supports that complex factors contribute a lot to the susceptibility of PD, which includes genetic and environmental factors \[[@B1]--[@B3]\]. In the past decades, a large number of Genome-Wide Association Studies (GWAS), Candidate Gene Replication Study (CGRS), and subsequent meta-analysis studies have found that a number of potential genes and single-nucleotide polymorphisms (SNPs) associated with PD, including both risk variants and protective variants \[[@B4]\]. In addition, the previous candidate genetic studies provided conclusive evidence showing SNPs in*LRRK2*,*SNCA*, and*ITGA8* genes significantly impact PD susceptibility and disease characteristics.

Several variations of*LRRK2* gene were identified as risk factors for PD. For example, rs34778348 (G2385R, c.7153G\>A) and rs33949390 (R1628P, c.4883G\>C) were seen to associate with PD in Asian population \[[@B5], [@B6]\]. Another novel SNP within*LRRK2*, rs1491942, was found to be responsible for PD in Caucasian populations \[[@B7], [@B8]\]. However, it was never reported in Chinese Han population before.

*SNCA*, as the first pathogenic gene identified in PD, encodes *α*-synuclein, the primary component of LB, the pathological hallmark of PD. From then on, several SNPs of*SNCA* were highly considered as the genetic risk factors for sporadic PD. Located in the promoter region of*SNCA*, two SNPs (rs2301134 and rs2301135) with high allele frequency were reported in some studies as PD-related SNPs in European and Taiwanese cohorts \[[@B9], [@B10]\]. One SNP (rs356221) in the 3′UTR region of*SNCA* gene showed association with susceptibility to sporadic PD in Japanese and Taiwanese cohorts \[[@B10], [@B11]\]. All these three SNPs of*SNCA* (rs2301134, rs2301135, and rs356221) have not been investigated in Han population on the Mainland of China.

While*ITGA8* (encoding integrin alpha 8, a type-I transmembrane protein) gene was firstly proved to connect with idiopathic PD in Caucasian population in Simón-Sánchez\'s study \[[@B4]\], it was not featured as a PD relevant gene until Lill\'s study revealed its potential association with PD \[[@B8]\]. Additional studies are needed to screen the potential pathogenic variants within this gene and assess the potential role of these variants in PD pathogenesis.

There are no study that explores the association of the three genes and their SNPs with Parkinson\'s disease in Chinese Han population. Here, we perform the first SNP replication study on previously published SNPs within*SNCA* (rs356221, rs2301134, and rs2301135),*LRRK2* (rs1491942), and*ITGA8* (rs7077361) gene in Chinese Han population to explore the ethnic differences and recognize predictive factors for the diagnosis of PD.

2. Methods {#sec2}
==========

2.1. Subjects {#sec2.1}
-------------

This study recruits 1136 cases in the Neurology Department of the First Affiliated Hospital of Xiamen University, which includes 583 Chinese Han sporadic PD patients and 553 matched healthy controls. PD diagnosis coincided well with the diagnostic criteria of UK Parkinson\'s Disease Society Brain Bank \[[@B12]\]. Among all the PD patients, the mean age is 65.10 ± 8.90 and the ratio of male to female patients is 320 : 263. The group of controls consists of healthy volunteers from the Medical Center of the First Affiliated Hospital of Xiamen University, the mean age of which is 65.37 ± 9.03, and the ratio of male to female patients is 286 : 267 ([Table 1](#tab1){ref-type="table"}). All subjects are Han population, and the two groups are matched for age, gender, ethnicity, and area of residence. Moreover, this study has gained approval of the local ethics committees, and all patients and controls signed informed consents.

2.2. Genetic Analysis {#sec2.2}
---------------------

Venous blood specimens are collected directly from all PD patients and the healthy controls with ethylene diamine tetraacetic acid (EDTA) anticoagulant. Genomic DNA is extracted from the blood samples with the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) under the manufacturer\'s instructions and stored at −20°C. The five SNPs are genotyped by Multiplex Snapshot technique (Applied Biosystems by Life Technologies, Foster City, CA, USA). The primers are designed for each SNP locus using Primer 5 and listed in [Table 2](#tab2){ref-type="table"}. Multiplex PCR reactions are performed to amplify target regions containing the selected SNPs. All products are analyzed by the ABI PRISM 3730 DNA Sequence, of which the sequence analyses are conducted by DNA Sequencing Analysis software, GeneMapper4.0. To confirm the results, 10% patients and 10% controls are randomly selected for Sanger sequencing approaches. The concordance rate for replicate approaches was 100%.

2.3. Statistical Analysis {#sec2.3}
-------------------------

The statistical analyses are processed with SPSS, version 20.0 (IBM, Armonk, NY, USA). The clinical data are expressed as the means ± standard deviation (SD) for the continuous variables and as numbers (percentage) for the quantitative variables. Student\'s*t*-test is used to compare the age variables between the patients and controls. The gender variables are assessed by the chi-square test. Differences in frequencies of the alleles and genotypes between cases and controls are tested for each SNP through Pearson\'s chi-square test and Fisher\'s exact test. The criterion for significance is set at *P* \< 0.05 based on two sides for all of the tests. The statistical power is calculated by Power and Sample Size Calculations version 3.1.2. The Hardy-Weinberg equilibrium (HWE) is tested by adopting the public statistics web tool (<http://ihg.gsf.de/cgi-bin/hw/hwa1.pl>). The Haploview program \[[@B13]\] is used for the calculation of linkage disequilibrium (LD) among the three SNPs in*SNCA.*

3. Results {#sec3}
==========

Genotype and allele frequencies of each SNP of all 1136 subjects (583 patients and 553 healthy controls) are shown in [Table 3](#tab3){ref-type="table"}. Among PD patients, 131 (22%) had an early age of onset (\<50 years) and around 77% of the patients were LOPD (≧50 years). The age (*P* = 0.860) and gender (*P* = 0.284) show no statistical difference between the PD patients and the controls in our study. All the subjects were ethnic Hans.

Linkage disequilibrium between the*SNCA* SNPs rs2301134 and rs356221 is *r* ^2^ = 0.235, while for rs356221 and rs2301135 it is *r* ^2^ = 0.066 and for rs2301134 and rs2301135 it is *r* ^2^ = 0.127. This shows weakly correlation with in rs2301134, rs2301135, and rs356221.

Single marker analysis showed a number of significantly statistical associations in our study. Two SNPs from*SNCA* and*LRRK2* genes displayed *P* values \< 0.05 prior to correction, both of which were estimated ORs \> 1.4. The best *P* value SNPs from both*LRRK2* and*SNCA* genes were further analyzed for age stratification.

Between all PD patients and controls,*LRRK2* gene showed a significant difference in the genotype frequency of variant rs1491942 (*P* = 3.543E − 09) and allelic G/C frequencies (*P* = 2.601E − 10, OR = 1.884, and 95% CI: 1.55--2.30). In the three SNPs of*SNCA* gene, only variant rs2301135 met the statistics standard in genotype frequencies (*P* = 4.39E − 07) and the allelic G/C frequencies (*P* = 9.116E − 13, OR = 7.857, and 95% CI: 4.05--15.26). The*ITGA8* variant rs7077361 failed to show significant difference in this group (*P* \> 0.05).

In the subgroup of EOPD patients and the controls (age \< 50 years), the differences were still obvious in the genotype frequencies of variant rs1491942 of*LRRK2* gene (*P* = 1.200E − 02) and allelic G/C frequencies (*P* = 3.028E − 03, OR = 1.924, and 95% CI: 1.24--2.98). Three SNPs of*SNCA* gene (*P* \> 0.05) and one SNP of*ITGA8* gene (*P* \> 0.05) failed to show significant difference in this group. Our statistic data of the LOPD patients and controls aged ≧ 50 years also surpassed the significance thresholds. The variant rs1491942 of*LRRK2* gene showed a *P* value of 2.538E-07 in genotype frequencies. And the allelic G/C frequencies have a *P* value of 2.459E-08 while the OR is 1.874, and the 95% CI ranged from 1.50 to 2.34. The difference is obvious in the variant rs2301135 of*SNCA* gene in the genotype frequencies (*P* = 5.561E − 07) and allelic G/C frequencies (*P* = 1.45E − 12, OR = 7.846, and 95% CI: 4.03--15.29) in the subgroup. All SNPs in our study met Hardy-Weinberg equilibrium except for the rs2301135 of*SNCA* gene, shown in [Table 3](#tab3){ref-type="table"}.

4. Discussion {#sec4}
=============

Since the first Genome-Wide Association Study on sporadic Parkinson\'s disease was performed in 2005, a new era starts to gain attention in the genetic basis of Parkinson\'s disease \[[@B14]\]. Advances in genotyping technology and meta-analysis have allowed researchers to rapidly identify common variants related to PD in different populations \[[@B4]\]. Though some of the previously nominated PD risk genes were firstly reported in familiar Parkinson\'s disease (such as*SNCA* and*LRRK2*), both of them were successfully replicated in unrelated sporadic PD patients \[[@B15]\]. Additional associated studies and subsequent meta-analysis contributed a lot to identifying the unnoticed variants that can also drive PD risk,*ITGA8* as an example \[[@B8]\].

*LRRK2* gene was firstly featured as a PD-related gene in Zimprich\'s study of families with autosomal-dominant, late-onset Parkinsonism in 2004 \[[@B16]\]. Variants in different domains of*LRRK2* have been identified in both familial and sporadic PD in different populations \[[@B17]--[@B19]\]. Rs1494942 in*LRRK2* was previously found associated with PD in US and European series \[[@B8], [@B20]\]. Our result, being consistent with previous studies, suggests that polymorphism rs1491942 of*LRRK2* is a risk loci of sporadic PD, and the variant carriers may share a similar pathomechanism in different populations. As it is reported,*LRRK2* variant carriers share similar clinical and pathological features, including a wild range of onset ages, typical Parkinsonism presentation, and sensitivity to L-dopa therapy \[[@B21]\]. In our PD patients, the rs1491942 shows significantly higher frequencies in both EOPD and LOPD subgroups compared with matched controls. These suggest that rs1491942 does not influence the onset age but contributes to the pathogenesis of EOPD and LOPD in a similar way.

*SNCA* is the first identified causal gene in familial PD \[[@B22]\]. Our findings are partly consistent with previous reports of the association of polymorphisms in*SNCA* with the susceptibility of PD in US, Norway, and Italian studies \[[@B23]--[@B25]\]. The linkage disequilibrium of three SNPs of*SNCA* gene showed that those SNPs are independent. Only one SNP near the promoter region (rs2301135) shows significant differences between PD patients and the controls in Chinese Han population. Concerning the age of onset, rs2301135 is more likely to associate with late-onset PD in our study, while another study in UK suggested that*SNCA* risk alleles for PD may associate with earlier onset of PD \[[@B26]\]. Given that genotype frequencies and allelic frequencies of rs2301135 of*SNCA* gene do not follow the Hardy-Weinberg equilibrium in our study, this suggests the possibility of inappropriate population stratification and selection or other confounding factors in our study. Therefore, these results should be interpreted carefully.

*ITGA8* expressing in brain mediates cell-cell interactions and regulates neurite outgrowth of sensory and motor neurons \[[@B8]\].*ITGA8* gene was firstly shown associated with PD in Caucasian population in Simón-Sánchez\'s study but failed to replicate in other studies of Greece, Irish, and Polish series \[[@B4], [@B19], [@B20]\].*ITGA8* variant rs7077361 showed no evidence of relation to PD in our population. In patients and controls, the observed MAFs of the SNP rs7077361 were similar to those reported in the 1000 genomes Southern Han Chinese (CHS) population. However, there is insufficient power to detect the association of rs7077361 with PD in the current sample size. The lack of association of the rs7077361 in Chinese Han population could be ascribed to the limited sample size and the rare existence of this SNP in Chinese population. Large-sample trials from multicenter are required to better understand the contribution of rs7077361 in*ITGA8* to PD susceptibility.

In conclusion, the present study provides considerable evidence to support the significant influence of genetic variants on PD risk. It does not replicate the susceptibility of rs2301134 and rs356221 in*SNCA* and rs7077361 in*ITGA8* for PD but confirms that single-nucleotide polymorphisms rs1491942 of*LRRK2* and rs2301135 of S*NCA* gene are susceptible to sporadic PD in Chinese Han population. Certain variants are responsible for the incidence of this disease, while other variants may modify the onset age, which suggests that distinct aspects of PD have a specific genetic architecture. Further studies are required to enrich genetic architecture of PD.
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###### 

Demographic characteristics of Parkinson\'s disease (PD) cases and controls.

  Characteristics                   Cases = 583   Controls = 553           
  --------------------------------- ------------- ---------------- ------- ------
  Gender (*n*, %)^*∗*^                                                      
   Female                           320           54.9             286     51.7
   Male                             263           45.1             267     48.3
  Age at collection (mean, SD)^†^   65.10         8.90             65.37   9.03
  Age at onset (*n*, %)                                                     
   \<50                             131           22.5             n.a.    n.a.
   ≧50                              452           77.5             n.a.    n.a.

All the subjects were ethnic Hans; ^*∗*^PD compared with controls by gender: *P* \> 0.05; ^†^PD compared with controls by age: *P* \> 0.05; n.a.: not applicable.

###### 

PCR and Snapshot probe primer sequences.

  Polymorphisms   Primers                       Sequence 5′ → 3′
  --------------- ----------------------------- -----------------------
  LRRK2                                          
   rs1491942      Forward                       CAGGCTTGGGCAATTTCTAA
  Reverse         GCCTATTGTGCTTCCTGCTC          
  Probe           40Ts+CAGGCTCCCCTGGGTT         
                                                
  SNCA                                           
   rs2301134      Forward                       ATCACGCTGGATTTGTCTCC
  Reverse         CACGGTCACAGGTTACAACG          
  Probe           41Ts+GACTCTTCCTTAGTAGTCTCCC   
   rs356221       Forward                       TGCCATAGAAACAACGAGGA
  Reverse         TTGAAGAACCCAAAATGCAA          
  Probe           24Ts+AAGAGAAGCCATCCTAGT       
   rs2301135      Forward                       ACTTAACGTGAGGCGCAAAA
  Reverse         CGTCCTCCTCCTCCTAGTCC          
  Probe           54Ts+CCGGGAGAGGGGCGGG         
                                                
  IGTA8                                          
   rs7077361      Forward                       TGCGAAAACTATTTGGTGAAA
  Reverse         CCCACCCACCAAATCTCTAA          
  Probe           31Ts+GAAATCATCTAGGGGATA       

###### 

Comparison of the genotype frequencies and the allele frequencies of *LRRK2*, *SNCA*, and *ITGA8* polymorphisms.

  Gene SNP           Group            Genotype *n*%   *P* ~HWE~   Allele Min/Maj   MAF^a^   MAF^b^   OR (95% CI)   *P*       Power^c^                                                                              
  ------------------ ---------------- --------------- ----------- ---------------- -------- -------- ------------- --------- ---------- ------ ----------------------- ----------------------- ------------------- ------
  *LRRK2*                                                                                                                                                                                                           
  rs1491942          Patients total   291             49.9        240              41.2     52       8.9           0.84      344/822    0.30   0.36                    1.884 (1.546--2.297)    2.60*E* − 10^*∗*^   1.00
  Controls total     372              67.3            161         29.1             20       3.6      0.67          201/905   0.18                                                                                  
  EOPD               65               49.6            54          41.2             12       9.2      0.84          78/184                      1.924 (1.244--2.976)    3.03*E* − 03^*∗*^                           
  Controls \< 50 y   74               68.5            29          26.9             5        4.6      0.33          39/177                                                                                          
  LOPD               226              50.0            186         41.2             40       8.8      0.82          266/638                     1.874 (1.500--2.340)    2.46*E* − 08^*∗*^                           
  Controls ≧ 50 y    298              67.0            132         29.7             15       3.4      0.87          162/728                                                                                         
                                                                                                                                                                                                                   
                                      GG              AG          AA                        A/G                                                                                                                    
                                                                                                                                                                                                                   
  *SNCA*                                                                                                                                                                                                            
  rs2301134          Patients total   437             75.0        132              22.6     14       2.4           0.29      160/1006   0.14   0.20                    1.237 (0.964--1.588)    9.43*E* -- 02       0.42
  Controls total     436              78.8            108         19.5             9        1.6      0.40          126/980   0.11                                                                                  
  EOPD               97               74.0            32          24.4             2        1.5      1.00          36/226                      1.561 (0.875--2.786)    1.29*E* − 01                                
  Controls \< 50 y   88               81.5            20          18.5             0        0.0      0.59          20/196                                                                                          
  LOPD               340              75.2            100         22.1             12       2.7      0.16          124/780                     1.176 (0.891--1.552)    2.52*E* − 01                                
  Controls ≧ 50 y    348              78.2            88          19.8             9        2.0      0.25          106/784                                                                                         
                                                                                                                                                                                                                   
                                      AA              TA          TT                        T/A                                                                                                                    
                                                                                                                                                                                                                   
  rs356221           Patients total   210             36.0        282              48.4     91       15.6          0.86      464/702    0.40   0.40                    1.167 (1.985--1.382)    7.50*E* − 02        0.45
  Controls total     231              41.8            244         44.1             78       14.1     0.31          400/706   0.36                                                                                  
  EOPD               43               32.8            67          51.1             21       16.0     0.59          109/153                     1.286 (0.887--1.864)    1.84*E* − 01                                
  Controls \< 50 y   46               42.6            47          43.5             15       13.9     0.67          77/139                                                                                          
  LOPD               167              36.9            215         47.6             70       15.5     1.00          355/549                     1.135 (0.938--1.374)    1.93*E* − 01                                
  Controls ≧ 50 y    185              41.6            197         44.3             63       14.2     0.36          323/567                                                                                         
                                                                                                                                                                                                                   
                                      CC              GG                           G/C                                                                                                                             
                                                                                                                                                                                                                   
  rs2301135          Patients total   544                         93.3             39                6.7           \<0.05    78/1088    0.07   0.19                    7.857 (4.046--15.258)   9.12*E* − 13^*∗*^   1.00
  Controls total     548                              99.1        5                         0.9      \<0.05        10/1096   0.01                                                                                  
  EOPD               129                              98.5        2                         1.5      \<0.05        4/258                       1.016 (1.000--1.031)    1.30*E* − 01                                
  Controls \< 50 y   108                              100.0       0                         0.0      \<0.05        0/216                                                                                           
  LOPD               415                              91.8        37                        8.2      \<0.05        74/830                      7.846 (4.026--15.288)   1.45*E* − 12^*∗*^                           
  Controls ≧ 50 y    440                              98.9        5                         1.1      \<0.05        10/880                                                                                          
                                                                                                                                                                                                                   
                                      TT              CT                           C/T                                                                                                                             
                                                                                                                                                                                                                   
  *ITGA8*                                                                                                                                                                                                           
  rs7077361          Patients total   580                         99.5             3                 0.5           1.00      3/1163     0.00   0.00                    2.85 (0.296--27.443)    6.25*E* − 01        0.34
  Controls total     552                              99.8        1                         0.2      1.00          1/1105    0.00                                                                                  
  EOPD               131                              100.0       0                         0.0      \<0.05        0/262                       0.995 (0.986--1.004)    4.52*E* − 01                                
  Controls \< 50 y   107                              99.1        1                         0.9      1.00          0/0                                                                                             
  LOPD               449                              99.3        3                         0.7      1.00          3/449                       1.003 (1.000--1.007)    2.50*E* − 01                                
  Controls ≧ 50 y    445                              100.0       0                         0.0      \<0.05        0/445                                                                                           

EOPD: early onset Parkinson\'s disease; LOPD: late-onset Parkinson\'s disease; *P* ~HWE~: *P* value obtained in the Hardy-Weinberg equilibrium (HWE) test; *∗*: significant *P* value obtained in the case-control analysis; Min: minor; Maj: major; MAF: minor allele frequency; a: this study; b: 1000 genomes (Southern Han Chinese); c: power was calculated by Power and Sample Size Calculations version 3.1.2.
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